Related Experiment Video
Updated: Oct 18, 2025
03:53
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
780
Ceftobiprole: a clinical view
P M Martínez Pérez-Crespo, L E López Cortés1
1Luis Eduardo López Cortés. Unidad de Gestión Clínica de Enfermedades Infecciosas y Microbiología. Hospital Universitario Virgen Macarena. Instituto de Biomedicina de Sevilla (IBIS). Seville, Spain. luiselopezcortes@gmail.com.
Summary
Ceftobiprole, a fifth-generation cephalosporin, shows strong bactericidal and anti-biofilm activity. Its effectiveness against complex infections like device-associated infections warrants further clinical investigation for optimal drug positioning.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Ceftobiprole is a fifth-generation cephalosporin antibiotic.
- It is approved for community-acquired and hospital-acquired pneumonia.
- Ceftobiprole demonstrates significant in vitro and animal model efficacy.
Purpose of the Study:
- To evaluate the potential of ceftobiprole in treating complex infections.
- To highlight its bactericidal and anti-biofilm properties.
- To identify areas for further clinical research.
Main Methods:
- In vitro studies assessing bactericidal and anti-biofilm activity.
- Animal models evaluating efficacy.
- Review of existing clinical data and potential applications.
Main Results:
- High bactericidal activity against various pathogens.
- Significant anti-biofilm properties demonstrated.
- Synergistic effects observed with other antibiotics against Gram-positive bacteria.
Conclusions:
- Ceftobiprole exhibits promising characteristics for treating complex infections.
- Its efficacy in device-associated infections and infective endocarditis requires further clinical validation.
- Additional clinical data are necessary for definitive drug positioning and expanded therapeutic use.
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
32
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
32
01:23Methods of Documentation V: CBE
1.2K
Charting by Exception, or CBE, is a method of documentation used in healthcare, particularly in nursing, that focuses on documenting only significant or abnormal findings rather than recording every detail. This approach aims to streamline the documentation process, improve efficiency, and ensure that healthcare providers can quickly identify deviations from normalcy in patient assessments.
In CBE, healthcare professionals establish predefined standards of practice that define what constitutes...
In CBE, healthcare professionals establish predefined standards of practice that define what constitutes...
1.2K
01:24Cystic Fibrosis: Management
254
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
254
01:28Antimicrobial Effectiveness
506
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
506
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
526
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
526
01:28Pneumonia IV: Management
503
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
503